MedTrace Logo

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

NCT00094328 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-06-26

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of muscles and sexual organs .

Conditions

  • Puberty, Precocious

Interventions

DRUG

Bicalutamide

oral

DRUG

Anastrozole

oral

Sponsors & Collaborators

Principal Investigators

  • Yuri E Rukazenkov, MD · AstraZeneca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
13 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-22
Primary Completion
2008-05-22
Completion
2017-12-06

Countries

  • United States
  • Canada
  • France
  • India
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00094328 on ClinicalTrials.gov